Greer Laboratories Overview

  • Year Founded
  • 1904

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 5

  • Investments
  • 1

Greer Laboratories General Information

Description

Provider of allergenic extracts in the United States for the diagnosis and treatment of allergies in both humans and animals. The company offers human and veterinary allergy products, including pollen, fungi and smuts, antigens, standardized and custom mixture, as well as epithelia, insect and miscellaneous inhalant extracts; as well as sterile diluting fluids, sterile empty vials and caps, safety syringes, syringes and syringe trays, vial trays and racks and skin testing devices.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • 639 Nuway Circle Northeast
  • PO Box 800
  • Lenoir, NC 28645
  • United States
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Other Services (B2C Non-Financial)
Corporate Office
  • 639 Nuway Circle Northeast
  • PO Box 800
  • Lenoir, NC 28645
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Greer Laboratories Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Greer Laboratories‘s full profile, request access.

Request a free trial

Greer Laboratories Patents

Greer Laboratories Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20140276197-A1 Apparatus and method for determining treatment endpoints for allergen testing Inactive 15-Mar-2013
US-20130231583-A1 Methods and compositions for injection delivery Inactive 02-Mar-2012
WO-2013130821-A1 Methods and compositions for injection delivery Inactive 02-Mar-2012
US-20050175638-A1 Desensitization immunotherapy; increasing concentration exposure regimen Active 06-Feb-2004
US-8491909-B2 Desensitization immunotherapy; increasing concentration exposure regimen Inactive 06-Feb-2004 A61K39/36
To view Greer Laboratories’s complete patent history, request access »

Greer Laboratories Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Greer Laboratories‘s full profile, request access.

Request a free trial

Greer Laboratories Investments (1)

Greer Laboratories’s most recent deal was a Buyout/LBO with Antigen Laboratories. The deal was made on 15-Apr-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Antigen Laboratories 15-Apr-2013 Buyout/LBO Laboratory Services (Healthcare)
To view Greer Laboratories’s complete investments history, request access »

Greer Laboratories FAQs

  • When was Greer Laboratories founded?

    Greer Laboratories was founded in 1904.

  • Where is Greer Laboratories headquartered?

    Greer Laboratories is headquartered in Lenoir, NC.

  • What industry is Greer Laboratories in?

    Greer Laboratories’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Greer Laboratories a private or public company?

    Greer Laboratories is a Private company.

  • What is Greer Laboratories’s current revenue?

    The current revenue for Greer Laboratories is .

  • Who are Greer Laboratories’s investors?

    Raymond James Capital has invested in Greer Laboratories.

  • When was Greer Laboratories acquired?

    Greer Laboratories was acquired on 08-Sep-2015.

  • Who acquired Greer Laboratories?

    Greer Laboratories was acquired by Stallergenes Greer.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process